InSilico Medicine Cayman TopCo (FRA:O15) Shares Outstanding (EOP): 557.42 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:O15 InSilico Medicine Cayman TopCo FRA:O15
20 GF Score
Price €5.25
! 3 Warning Signs
View Full Analysis

What is InSilico Medicine Cayman TopCo Shares Outstanding (EOP)?

InSilico Medicine Cayman TopCo FRA:O15 +3.96% 20 Shares Outstanding (EOP) is 557.42 Mil as of Dec. 2025. GuruFocus rates FRA:O15 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. InSilico Medicine Cayman TopCo's shares outstanding for the quarter that ended in Dec. 2025 was 557.42 Mil.

InSilico Medicine Cayman TopCo's quarterly shares outstanding stayed the same from Jun. 2025 (557.42 Mil) to Dec. 2025 (557.42 Mil).

InSilico Medicine Cayman TopCo's annual shares outstanding stayed the same from Dec. 2024 (557.42 Mil) to Dec. 2025 (557.42 Mil).


InSilico Medicine Cayman TopCo  (FRA:O15) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


InSilico Medicine Cayman TopCo Shares Outstanding (EOP) Related Terms


InSilico Medicine Cayman TopCo Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for InSilico Medicine Cayman TopCo's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InSilico Medicine Cayman TopCo Shares Outstanding (EOP) Chart

InSilico Medicine Cayman TopCo Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
557.42 557.42 557.42 557.42

InSilico Medicine Cayman TopCo Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial 557.42 557.42 557.42 557.42 557.42

FRA:O15 vs MSFT, ORCL, PLTR: Shares Outstanding (EOP) Comparison

For the Software - Infrastructure subindustry, InSilico Medicine Cayman TopCo's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InSilico Medicine Cayman TopCo Shares Outstanding (EOP) vs Software Industry

For the Software industry and Technology sector, InSilico Medicine Cayman TopCo's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where InSilico Medicine Cayman TopCo's Shares Outstanding (EOP) falls into.


FRA:O15
20GF Score
InSilico Medicine Cayman TopCo FRA:O15
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InSilico Medicine Cayman TopCo Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 557.42 Mil mean?
InSilico Medicine Cayman TopCo (FRA:O15) has a Shares Outstanding (EOP) of 557.42 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on InSilico Medicine Cayman TopCo and its competitors.
Is InSilico Medicine Cayman TopCo's Shares Outstanding (EOP) too high?
InSilico Medicine Cayman TopCo's current Shares Outstanding (EOP) is 557.42 Mil. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's Shares Outstanding (EOP) compare to MSFT and ORCL?
InSilico Medicine Cayman TopCo's Shares Outstanding (EOP) of 557.42 Mil can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Software company?
A good Shares Outstanding (EOP) depends on the Software industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on InSilico Medicine Cayman TopCo and its competitors. InSilico Medicine Cayman TopCo's current Shares Outstanding (EOP) is 557.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (FRA:O15) has a current Shares Outstanding (EOP) of 557.42 Mil. The current Shares Outstanding (EOP) is 557.42 Mil. InSilico Medicine Cayman TopCo's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (FRA:O15), the current Shares Outstanding (EOP) is 557.42 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

InSilico Medicine Cayman TopCo Business Description

Other Exchanges 03696:Hong Kong
Address Hong Kong Science Park, Unit 310, 3rd Floor, Building 8W, Phase 2, Pak Shek Kok, New Territories, Hong Kong, HKG
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
20GF Score

Get the complete analysis for FRA:O15

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.25
Price